Israel’s Teva Pharmaceuticals has reported success in the Phase IIa clinical trial of Laquinimod in moderate to severe Crohn’s disease. The announcement was made at the 20th United European Gastroenterology (UEG) conference in Amsterdam.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000792018